Articles On Race Oncology (ASX:RAC)

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

Tax-loss selling could be pile-driving fundamentally good companies into the ground. At least, that's what analysts at Macquarie think, prompting the team to name a handful of ASX shares to buy following the indiscriminate tax-driven sellin...

It was an unpleasant Wednesday for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares this hump day. After enjoying a strong session yesterday, investors reversed course to...

  Race Oncology says non-clinical toxicology and safety studies of lead drug RC220 Bisantrene successfully completed RC220 demonstrated excellent safety profile, including safe administration via peripheral IV infusion Studies support star...

Cleo commences FDA process Cleo Diagnostics (ASX:COV) has announced significant progress in advancing its regulatory strategy for its pre-surgical triage test designed to detect ovarian cancer. Recently, Cleo conducted an initial pre-submis...

The S&P/ASX 200 Index (ASX: XJO) is having a tough time on Wednesday after a stronger than expected inflation reading. In afternoon trade, the benchmark index is down 1% to 7,758.4 points. Four ASX shares that are not letting that hold...

After closing up 1.4% on Tuesday, the S&P/ASX 200 Index (ASX: XJO) looks ready to give back most of those gains today. The benchmark index was down 0.5% at 11.30am AEST. Then, the Australian Bureau of Statistics (ABS) released May's Au...

Race Oncology Ltd (ASX: RAC) shares burst out of the gates on Wednesday morning. In early trade, the ASX healthcare stock was up as much as 15% to $1.96. The clinical stage biopharmaceutical company's shares have eased back a touch since th...

For biotech investors, the news of an approval by the US FDA is a genuinely exciting milestone. The FDA is the ultimate gatekeeper for the US pharmaceutical market, which is by far the world’s largest. Approval from the FDA not only validat...

With the S&P/ASX 200 Health Care Index (ASX: XHJ) dipping slightly into the red on Wednesday, it's been a different story for three individual ASX healthcare shares. Pro Medicus Limited (ASX: PME), Race Oncology Ltd (ASX: RAC), and...

S&P/ASX 200 Index (ASX: XJO) gold stocks enjoyed a blistering rally from late February through to late May this year. That rally was driven by a surge in the gold price. On 28 February, the yellow metal was trading for US$2,030 per oun...

The ASX 200 has finished the day up a per cent, after interest rates were kept on hold at 4.35%, firmly in line with predictions. Australia’s Big 4 and major investment banks were all calling for a June hold decision. However, Morgan St...

ASX rose  as the RBA held interest rates at 12-year high 4.35pc All 11 sectors on the ASX gained, with significant moves from Pilbara and Fortescue  ASX to launch first bitcoin-linked ETF on Thursday   Aussie stocks bounced back by +0.8%...

US FDA extends Rare Paediatric Disease Designation (RPDD) to Race Oncology’s novel RC220 bisantrene drug RPDD gives RC220 eligibility to receive a Priority Review Voucher (PRV) upon marketing approval PRV’s can be transferred or sold to ot...

The S&P/ASX 200 Index (ASX: XJO) is back on form on Tuesday and storming higher. In afternoon trade, the benchmark index is up 0.95% to 7,773.6 points. Four ASX shares that are rising more than most today are listed below. Here's why t...

Race Oncology Ltd (ASX: RAC) shares are roaring higher on Tuesday morning. In early trade, the ASX healthcare stock is up 11% to $1.94. Why is this ASX healthcare stock surging? Investors have been buying the clinical stage biopharmaceutica...

Race Oncology (ASX:RAC) has announced that the US FDA has extended Rare Paediatric Disease Designation to RC220 bisantrene to treat paediatric subtypes of acute myeloid leukemia.

Race Oncology (ASX:RAC) has announced a preclinical breakthrough in heart toxicity side effects caused by the carfilzomib, which had precluded the drug being administered to patients diagnosed with elevated cardiac risk factors. In work...

Race Oncology (ASX:RAC) has reported the results of preclinical work performed under contract by US-based Labcorp of a mouse model involving bisantrene in combination with carfilzomib.

The S&P/ASX 200 Index (ASX: XJO) endured a horror return for the short trading week this Tuesday, crashing by a depressing 1.33%. By the time the market closed, the ASX 200 was sittin...

Aussie shares slipped over 1pc after the King’s Birthday long weekend Mining and Real Estate sectors were the biggest losers among all 11 sectors Chinese EV stocks fell ahead of expected EU tariff hikes   Aussie shares slipped after the K...

  US FDA extends orphan drug designation to Race’s re-formulated RC220 bisantrene drug product for treatment of Acute Myeloid Leukemia Orphan drug designation has a range of commercial advantages including seven years market exclusivity in...

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. Some might think Apple Inc's (NASDAQ: AAPL) best days are behind it. Revenue growth has ground to a halt. The company's bigge...

The S&P/ASX 200 Index (ASX: XJO) is having a very tough start to the week. In afternoon trade, the benchmark index is down 1.45% to 7,745.6 points. Four ASX shares that are not letting that hold them back today are listed below. Here's...

Orthocell (ASX:OCC) has taken a significant step forward in its efforts to introduce its SmrtGraft product to the Australian market. The company has submitted an application to the Therapeutic Goods Administration (TGA) seeking approval to...

The S&P/ASX 200 Index (ASX: XJO) is down 1.1% today, but you can't blame this rocketing ASX 200 share. Shares in the auto parts company closed on Friday trading for $4.36. In earlier trade on Tuesday, shares were swapping hands for $...

Race Oncology (ASX: RAC) has achieved a significant breakthrough with the US Food and Drug Administration (FDA) awarding orphan drug designation (ODD) to the company’s acute myeloid leukemia (AML) candidate bisantrene RC220. The coveted des...

Deciding which ASX dividend shares to buy can be a gruelling process. Luckily for income investors, analysts have done a lot of the hard work for you and picked out two they think are buys. Here's what they are saying about these dividend s...

Investors tend to consider ASX 200 bank shares as dividend payers rather than growth investments, with two exceptions — Commonwealth Bank of Australia (ASX: CBA) and Macquarie Group Ltd (ASX: MQG). And there's good reason for those excep...

The work of pharmaceutical companies can bring new hope to patients delivering solutions to unmet medical needs. It can also turn a small market cap play into a giant – but it’s a process that’s not easy, it’s risky and it can take a lot of...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Investors that are on the lookout for some big returns might want to check out these ASX 200 shares listed below. That's because analysts are tipping their shares to deliver returns of between 15% and 50% for investors over the next 12 mont...

The conventional wisdom on the ASX exchange-traded fund (ETF) landscape is that index funds offer investors the lowest fees. Amongst all ETFs on the Australian markets, the lowest charging are all index funds that cover either ASX or Americ...

The ASX200 closed the day down 0.3 of a per cent. Aside from consumer discretionary and healthcare, all other sectors ended in the red. The latest data from ANZ on Australian consumer spending shows that activity has increased 5.7% ov...

It was a dastardly Tuesday for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares during today's trading. The ASX 200 finished up with its tail between its legs...

ASX retreats on Tuesday ahead of Fed Budget and US PPI/CPI Copper stocks up after the metal hit highest level since 2022 GUD jumps 11pc after strong FY24 update   The ASX dipped by -0.4% on Tuesday ahead of the Federal Budget and a key PP...

G'day Treasurer, I'm glad I've caught you in time. I know you have a Budget to hand down in a few hours. And I know it's already printed, so it's a bit late to make changes. But I know you're a good man, and you want to make sure you've lef...

Bisantrene and decitabine used together offer significantly improved cancer cell-killing across 143 tumour cell lines than either drug used alone Results support the use of decitabine in combination with bisantrene as a potential new treat...

The S&P/ASX 200 Index (ASX: XJO) is having a tough session on Tuesday. In afternoon trade, the benchmark index is down 0.4% to 7,719.1 points. Four ASX shares that are not letting that hold them back today are listed below. Here's why...

The ASX200 is tracking lower than expected, down nearly a quarter of a per cent. The health care sector is leading intraday gains, up more than 0.5%. Real estate has fallen the most, down around 0.8%, Staples follows closely behind down...

ASX healthcare shares are one of only two market sectors trading in the green at the time of writing. The S&P/ASX 200 Health Care Index (ASX: XHJ) is up 0.55% and is the best sector of the day so far. These two ASX healthcare sha...

One of my personal investing mottos is "the market is straight up kooky dooks". Not only did I think of this saying again today, I also felt it fitting that it was paraphrased from a movie – in this case the Disney (NYSE: DIS) animated...

Race Oncology says bisantrene + decitabine effective Race Oncology (ASX:RAC) jumped 8% this morning after sharing the results from recent preclinical studies conducted at Oncolines B.V. in the Netherlands. In these studies, bisantrene (Race...

S&P/ASX 200 Index (ASX: XJO) stock GUD Holdings Ltd (ASX: GUD) is off to the races on Tuesday. Shares in the diversified automotive market products company closed yesterday trading for $9.77. At the time of writing in late morning tr...

Race Oncology (ASX:RAC) has shared the results from recent preclinical work performed under contract at Oncolines in the Netherlands, combining bisantrene with decitabine.

Race Oncology (ASX:RAC) had caught the eyes of HotCopper users pre-market on Tuesday as the company reported enhancement of its ability to kill cancer cells – to be further explored in a proposed Phase I/II leukaemia trial. That enhance...

Race Oncology (ASX:RAC) had caught the eyes of HotCopper users pre-market on Tuesday as the company reported enhancement of its ability to kill cancer cells – to be further explored in a proposed Phase I/II leukaemia trial. That enhance...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Several ASX companies are repurposing or resurrecting abandoned or under utilised drugs  Paradigm Biopharmaceuticals identified the potential of FDA-approved PPS that has a long track record of treating inflammation Starpharma has develope...